Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A study titled “Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes,” published in the December 2023 issue of The American Journal of Managed Care® (AJMC®), was referenced in articles from Physician’s Weekly, DocWire News, and HCPLive. The study found that approximately 40% of patients with type 2 diabetes discontinued their second-line therapies within a year.
An article from Medriva referenced an article published on AJMC.com, the website of AJMC. The article, “Top 5 Conference Coverage of 2023,” collected the most-viewed items on AJMC.com that reported on new research presented at medical conferences that AJMC editors attended throughout the year, including the Annual Meeting of the American Society of Clinical Oncology and the European Hematology Association Congress.
Health Equity and Access Weekly Roundup: May 4, 2024
May 4th 2024This week, the Center on Health Equity and Access highlights a variety of gaps that exist in health care, spanning women's health, the rising rate of metabolic disease, and policy for LGBTQ+ and immigrant populations. The consensus among featured experts points to comprehensive care models.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More